

For personal use only

# **Nexsen Limited**

## **Consolidated Financial Statements**

**For the Year Ended 30 June 2025**

**Nexsen Limited**

**Contents**

**For the Year Ended 30 June 2025**

	Page
<b>Consolidated Financial Statements</b>	
Corporate Directory	1
Directors' Report	2
Auditor's Independence Declaration under Section 307C of the Corporations Act 2001	6
Consolidated Statement of Profit or Loss and Other Comprehensive Income	7
Consolidated Statement of Financial Position	8
Consolidated Statement of Changes in Equity	9
Consolidated Statement of Cash Flows	10
Notes to the Financial Statements	11
Consolidated Entity Disclosure Statement	24
Directors' Declaration	25
Independent Audit Report	26

For personal use only

**Nexsen Limited**

**Corporate Directory**

**30 June 2025**

**Board of Directors**

Reece O'Connell, Executive Chairman (appointed 9 June 2025)

Mark Anthony Muzzin, Managing Director

Thomas Sylvanus Hanly, Managing Director (resigned 11 July 2025)

Gavin Neil Ball, Non-Executive Director (resigned 4 June 2025)

Martina Mariano, Non-Executive Director

**Company Secretary**

Mark Anthony Muzzin (resigned 26 February 2025)

Justin Mouchacca (resigned 26 February 2025)

Sonny Didugu (appointed 26 February 2025)

**Registered Office & Principal Place of Business**

Registered office: SUITE 1005 , 4 BRIDGE STREET , SYDNEY NSW 2000

Principal Place of Business: UNIT 10 L , 440 COLLINS STREET , MELBOURNE VIC 3000

**Auditor**

Moore Australia Audit (WA)

**Website**

[www.nexsen.bio](http://www.nexsen.bio)

## Nexsen Limited

# Directors' Report

## 30 June 2025

The directors present their report, together with the consolidated financial statements of the Group, being the Company and its controlled entities, for the financial year ended 30 June 2025.

### Director Information

#### Information on directors

Mark Anthony Muzzin

Qualifications

Mark has had more than 30 years of commercial experience working with both Australian and international public and private companies. He served as the Managing Director/CEO of an ASX-listed entity from 2008 to 2016. Since 2009, Mark has been working with various academic institutions to commercialise IP, primarily in 2D materials and in biosensors. He is also an industry liaison for the Australian Research Council (ARC) Centre of Excellence in Future Low-Energy Electronics Technologies.

Thomas Sylvanus Hanly

Qualifications

Thomas has a strong understanding of capital markets and a passionate interest in technology. He was previously Managing Director and CEO of the ASX-listed Singular Health Group and has held a number of board positions of companies in Australia and Singapore. His experience with the funding and commercialisation of innovative technologies has recently seen him involved with several ground-breaking projects.

Gavin Ball

Qualifications

Gavin is a business manager who adds strength to each of the companies with whom he works. He has over 30-years of hands-on skill and intellectual expertise in the start-up, commercial development, growth and ongoing management of businesses, and has proven management, financial and accounting skill sets, with a strong sales and marketing focus. Gavin has both current and past experience as a Commercial Manager and Company Director of ASX-listed companies.

Martina Mariano

Qualifications

With a well-rounded knowledge of the MedTech landscape, Martina brings a unique ability to seamlessly integrate innovation, scientific rigour, and business acumen to accelerate the commercialisation of cutting-edge medical technologies. She has over a decade of experience in the medical field working and studying in Europe, the US, and Australia. These roles have included the Italian Carabinieri Police Force (Forensic Genetic Department), a PhD in Medicine (Perth, UWA), and as Chief Commercial Officer at the ASX-listed company Singular Health Group.

Reece O'Connell

Qualifications

Mr O'Connell is a seasoned financial professional and accomplished fund manager with over a decade of experience in capital markets, specialising in high-growth sectors including biotechnology. He is the founding Fund Manager of the Summit Biotech Fund, recognised as one of Australia's best-performing small-cap biotech funds, consistently delivering annualised returns exceeding 30% and raising over \$100 million in investor capital. Mr O'Connell's expertise spans equity trading, portfolio construction, capital raising, and strategic corporate advisory, underpinned by a BA in Finance and an MBA in Innovation and Leadership. Mr O'Connell brings a unique perspective at the intersection of finance and innovation strategy, with deep networks in institutional investment and biotech commercialisation.

**Nexsen Limited****Directors' Report****30 June 2025****Company secretaries**

At the end of the financial year, and at present, the sole Company Secretary is Sonny Dudugu.

During the financial year, Mark Anthony Muzzin and Justin Mouchacca, CA served as joint Company Secretaries until 28 February 2025. Mark Anthony Muzzin has held the role since 2021 and previously served as Managing Director/CEO of an ASX-listed entity from 2008 to 2016. Justin Mouchacca was appointed in 2024 and has extensive experience in corporate secretarial services.

**Meetings of directors**

During the financial year, 2 meetings of directors were held. Attendances by each director during the year were as follows:

	<b>Directors' Meetings</b>	
	<b>Number eligible to attend</b>	<b>Number attended</b>
Mark Anthony Muzzin	2	2
Thomas Sylvanus Hanly	2	2
Gavin Ball	1	1
Reece O'Connell	1	1
Martina Mariano	2	2

**Principal activities**

The principal activities of the Group during the financial year were development of a new nano-biotech sensor and point-of-care rapid test for the detection of Group B Streptococcus.

No significant change in the nature of these activities occurred during the year.

**Significant changes in state of affairs**

The following significant changes in the state of affairs of the parent entity occurred during the financial year:

- In February 2025, the Company completed the issue of convertible notes, raising a total of \$3 million as part of its financing strategy before going public (pre-IPO).
- In February 2025, the Company acquired the remaining intellectual property rights it did not already own in respect of the Strepsure Sensor from RMIT University for consideration comprising the issue of 6 million fully paid ordinary shares at \$0.20 each and \$250,000 in cash.

Except for matters noted above, there have been no other significant changes in the state of affairs of the Company during the year.

## Nexsen Limited

# Directors' Report

30 June 2025

### Operating results and review of operations for the year

#### Operating results

The consolidated profit/(loss) of the Group amounted to \$ (5,021,842) (2024: \$ 827).

#### Review of operations

A review of the operations of the Group during the financial year and the results of those operations show an increase in revenue of 0.3M and increase in total expenses of 5.3M resulting in an decrease of profit before taxation of 5.0M.

#### Dividends paid or recommended

No dividends were paid or declared since the start of the financial year. No recommendation for payment of dividends has been made.

#### Events after the reporting date

No matters or circumstances have arisen since the end of the financial year which significantly affected or may significantly affect the operations of the Group, the results of those operations or the state of affairs of the Group in future financial years.

#### Future developments and results

By March 2025, the Company had raised \$1.4 million in equity, secured a \$3 million federal grant, and received \$2.5 million in support from RMIT and partners, with an additional \$1.5 million to be self-funded for the GBS Rapid Sensor. The goal is to achieve regulatory approvals in multiple jurisdictions. The Company now plans an IPO raise and to pursue an ASX listing in the coming months.

#### Environmental issues

The Group's operations are not regulated by any significant environmental regulations under a law of the Commonwealth or of a state or territory of Australia.

#### Options

There have been no unissued shares or interests under option in the Company or a controlled entity during or since reporting date.

#### Indemnification and insurance of officers and auditors

No indemnities have been given or insurance premiums paid, during or since the end of the financial year, for any person who is or has been an officer or auditor of Nexsen Limited.

#### Proceedings on behalf of group

No person has applied for leave of court under Section 237 of the *Corporations Act 2001* to bring proceedings on behalf of the Company or intervene in any proceedings to which the Company is a party for the purpose of taking responsibility on behalf of the Company for all or any part of those proceedings. The company was not a party to any such proceedings during the year.


**Nexsen Limited**

**Directors' Report**  
**30 June 2025**

**Auditor's independence declaration**


The lead auditor's independence declaration in accordance with section 307C of the *Corporations Act 2001*, for the year ended 30 June 2025 has been received and can be found on page 6 of the consolidated financial report.

Signed in accordance with a resolution of the Board of Directors:

Signed by:  


Director: .....6217F44D07CF49C.....

Mark Anthony Muzzin

Signed by:  


Director: .....497B543B661B438.....

Reece O'Connell

Dated 21 August 2025

For personal use only

**AUDITOR'S INDEPENDENCE DECLARATION  
UNDER SECTION 307C OF THE CORPORATIONS ACT 2001  
TO THE DIRECTORS OF NEXSEN LIMITED**

I declare that, to the best of my knowledge and belief, during the year ended 30 June 2025, there have been:

- a) no contraventions of the auditor independence requirements as set out in the *Corporations Act 2001* in relation to the audit, and
- b) no contraventions of any applicable code of professional conduct in relation to the audit.



NEIL PACE  
PARTNER



MOORE AUSTRALIA AUDIT (WA)  
CHARTERED ACCOUNTANTS

Signed at Perth this 21<sup>st</sup> day of August 2025.

## Nexsen Limited

**Consolidated Statement of Profit or Loss and Other Comprehensive Income**

For the Year Ended 30 June 2025

	Note	2025 \$	2024 \$
<b>Income</b>			
Revenue	4	<u>931,605</u>	631,863
<b>Total income</b>		<u>931,605</u>	631,863
<b>Expenses</b>			
Employee benefits expense		(472,810)	(67,458)
Project expenses		(2,122,613)	(177,284)
Marketing expenses		(35,903)	(25,122)
Finance expenses	5	(2,342,407)	(66,846)
Other expenses		<u>(979,714)</u>	<u>(277,263)</u>
<b>Total expenses</b>		<u>(5,953,447)</u>	<u>(613,973)</u>
<b>Profit before income tax</b>		(5,021,842)	17,890
Income tax expense		-	(17,063)
<b>Profit /(Loss) for the year</b>		<u>(5,021,842)</u>	<u>827</u>
<b>Other comprehensive income, net of income tax</b>		-	-
<b>Other comprehensive income for the year, net of tax</b>		-	-
<b>Total comprehensive income /(loss) for the year</b>		<u>(5,021,842)</u>	<u>827</u>

The accompanying notes form part of these financial statements.

For personal use only

## Nexsen Limited

## Consolidated Statement of Financial Position

As At 30 June 2025

	Note	2025 \$	2024 \$
<b>ASSETS</b>			
CURRENT ASSETS			
Cash and cash equivalents	6	423,104	591,522
Trade and other receivables	7	230,284	49,815
Current tax receivable		639,668	186,094
TOTAL CURRENT ASSETS		<u>1,293,056</u>	<u>827,431</u>
NON-CURRENT ASSETS			
Intangible assets	8	1,964,629	683,510
TOTAL NON-CURRENT ASSETS		<u>1,964,629</u>	<u>683,510</u>
TOTAL ASSETS		<u><u>3,257,685</u></u>	<u><u>1,510,941</u></u>
<b>LIABILITIES</b>			
CURRENT LIABILITIES			
Trade and other payables	9	253,929	145,343
Other financial liabilities	10	3,120,000	-
TOTAL CURRENT LIABILITIES		<u>3,373,929</u>	<u>145,343</u>
NON-CURRENT LIABILITIES			
TOTAL NON-CURRENT LIABILITIES		<u>-</u>	<u>-</u>
TOTAL LIABILITIES		<u>3,373,929</u>	<u>145,343</u>
NET ASSETS		<u><u>(116,244)</u></u>	<u><u>1,365,598</u></u>
<b>EQUITY</b>			
Issued capital	11	2,521,561	1,321,561
Reserves		2,592,310	252,310
Retained earnings		(5,230,115)	(208,273)
TOTAL EQUITY		<u><u>(116,244)</u></u>	<u><u>1,365,598</u></u>

The accompanying notes form part of these financial statements.

**Nexsen Limited**

**Consolidated Statement of Changes in Equity**

**For the Year Ended 30 June 2025**

**2025**

**Balance at 1 July 2024**

Profit attributable to members of the parent entity

Issue of shares

Convertible notes

**Balance at 30 June 2025**

**2024**

**Balance at 1 July 2023**

Profit attributable to members of the parent entity

Issue of shares

Convertible notes

**Balance at 30 June 2024**

Ordinary Shares	Retained Earnings	General Reserve	Total
\$	\$	\$	\$
1,321,561	(208,273)	252,310	1,365,598
-	(5,021,842)	-	(5,021,842)
1,200,000	-	-	1,200,000
-	-	2,340,000	2,340,000
<b>2,521,561</b>	<b>(5,230,115)</b>	<b>2,592,310</b>	<b>(116,244)</b>

Ordinary Shares	Retained Earnings	General Reserve	Total
\$	\$	\$	\$
23,501	(209,100)	-	(185,599)
-	827	-	827
1,298,060	-	-	1,298,060
-	-	252,310	252,310
<b>1,321,561</b>	<b>(208,273)</b>	<b>252,310</b>	<b>1,365,598</b>

The accompanying notes form part of these financial statements.

## Nexsen Limited

## Consolidated Statement of Cash Flows

### For the Year Ended 30 June 2025

	Note	2025 \$	2024 \$
<b>CASH FLOWS FROM OPERATING ACTIVITIES:</b>			
Receipts from grants		1,133,352	771,268
Payments to suppliers and employees		(4,340,651)	(797,753)
Income taxes paid		-	(17,063)
<b>Net cash used in operating activities</b>	19	<b>(3,207,299)</b>	<b>(43,548)</b>
<b>CASH FLOWS FROM INVESTING ACTIVITIES:</b>			
Purchase of intangible assets		(81,119)	(262,624)
<b>Net cash used in investing activities</b>		<b>(81,119)</b>	<b>(262,624)</b>
<b>CASH FLOWS FROM FINANCING ACTIVITIES:</b>			
Proceeds from issue of shares		-	1,048,060
Proceeds from borrowings		3,120,000	-
Payment of borrowings		-	(164,180)
<b>Net cash provided by financing activities</b>		<b>3,120,000</b>	<b>883,880</b>
<b>Net increase/(decrease) in cash and cash equivalents held</b>		<b>(168,418)</b>	<b>577,708</b>
Cash and cash equivalents at beginning of year		591,522	13,814
<b>Cash and cash equivalents at end of financial year</b>	6	<b>423,104</b>	<b>591,522</b>

The accompanying notes form part of these financial statements.

## Nexsen Limited

# Notes to the Financial Statements

## For the Year Ended 30 June 2025

The consolidated financial report covers Nexsen Limited and its controlled entities ('the Group'). Nexsen Limited is a for-profit propriety, public company, incorporated and domiciled in Australia.

The consolidated financial statements are presented in Australian dollars which is the parent entity's functional and presentation currency.

The financial report was authorised for issue by the Directors on .

Comparatives are consistent with prior years, unless otherwise stated.

### 1 Basis of Preparation

The financial statements are general purpose financial statements that have been prepared in accordance with the Australian Accounting Standards and the *Corporations Act 2001*. These financial statements also comply with International Financial Reporting Standards as issued by the International Accounting Standards Board.

#### Going concern

The financial report has been prepared on the going concern basis that contemplates the continuity of normal business activities and the realisation of assets and extinguishment of liabilities in the ordinary course of business.

For the financial year ended 30 June 2025, the Company incurred a substantial operating loss \$5,021,842 and as at 30 June 2025 had a working capital \$(2,080,873) and net assets deficiency \$116,244.

The Company has prepared a cash flow forecast for the next 12 months, which indicate that the ability of the Company to continue as a going concern is primarily dependent on an expected capital raise pursuant to a planned IPO expected to be completed within the coming months.

Notwithstanding the current deficiency of net assets and after taking into account current cash resources of the Company, the planned capital raise and the cashflow forecast referred to above, the Directors consider the going concern basis of preparation to be appropriate for the preparation of this financial report.

Material accounting policy information is consistent with prior reporting periods unless otherwise stated.

### 2 Material Accounting Policy Information

#### (a) Basis for consolidation

The consolidated financial statements include the financial position and performance of controlled entities from the date on which control is obtained until the date that control is lost.

All controlled entities have the same financial year end as the parent.

#### *Subsidiaries*

Subsidiaries are all entities (including structured entities) over which the parent has control. Control is established when the parent is exposed to or has rights to variable returns from its involvement with the entity and has the ability to affect those returns through its power to direct the relevant activities of the entity.

**Nexsen Limited****Notes to the Financial Statements  
For the Year Ended 30 June 2025****2 Material Accounting Policy Information****(b) Revenue and other income****Grant revenue**

Grants relating to expense items are recognised as income over the periods necessary to match the grant to the costs they are compensating, but only upon the satisfaction of applicable performance obligations.

Grants relating to assets are credited to deferred income at fair value and are credited to income over the expected useful life of the asset on a straight-line basis.

**(c) Income tax**

The tax expense recognised in the consolidated statement of profit or loss and other comprehensive income comprises current income tax expense plus deferred tax expense.

Current tax is the amount of income taxes payable (recoverable) in respect of the taxable profit (loss) for the year and is measured at the amount expected to be paid to (recovered from) the taxation authorities, using the tax rates and laws that have been enacted or substantively enacted by the end of the reporting period. Current tax liabilities (assets) are measured at the amounts expected to be paid to (recovered from) the relevant taxation authority.

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply to the period when the asset is realised or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period.

Deferred tax assets are recognised for all deductible temporary differences and unused tax losses to the extent that it is probable that taxable profit will be available against which the deductible temporary differences and losses can be utilised.

**(d) Goods and services tax (GST)**

Revenue, expenses and assets are recognised net of the amount of goods and services tax (GST), except where the amount of GST incurred is not recoverable from the Australian Taxation Office (ATO).

Receivables and payable are stated inclusive of GST.

Cash flows in the consolidated statement of cash flows are included on a gross basis and the GST component of cash flows arising from investing and financing activities which is recoverable from, or payable to, the taxation authority is classified as operating cash flows.

**(e) Financial instruments**

Financial instruments are recognised initially on the date that the Group becomes party to the contractual provisions of the instrument.

On initial recognition, all financial instruments are measured at fair value plus transaction costs (except for instruments measured at fair value through profit or loss where transaction costs are expensed as incurred).

**Nexsen Limited****Notes to the Financial Statements  
For the Year Ended 30 June 2025****2 Material Accounting Policy Information****(e) Financial instruments****Financial assets***Amortised cost*

The Group's financial assets measured at amortised cost comprise cash and cash equivalents and trade and other receivables in the consolidated statement of financial position.

*Trade receivables*

Impairment of trade receivables and contract assets have been determined using the simplified approach in AASB 9 which uses an estimation of lifetime expected credit losses.

The amount of the impairment is recorded in a separate allowance account with the loss being recognised in finance expense. Once the receivable is determined to be uncollectable then the gross carrying amount is written off against the associated allowance.

Where the Group renegotiates the terms of trade receivables due from certain customers, the new expected cash flows are discounted at the original effective interest rate and any resulting difference to the carrying value is recognised in profit or loss.

**Financial liabilities**

The financial liabilities of the Group comprise trade and other payables and convertible notes.

**(f) Cash and cash equivalents**

Cash and cash equivalents comprises cash on hand, demand deposits and short-term investments which are readily convertible to known amounts of cash and subject to an insignificant risk of change in value.

**(g) Trade and other receivables**

Trade receivables are initially recognised at fair value and subsequently measured at amortised cost using the effective interest method, less any expected credit losses. Trade receivables are generally due for settlement within 30 days.

Collectability of trade receivables is reviewed on an ongoing basis. Debts which are known to be uncollectable are written off by reducing the carrying amount directly. A provision for impairment of trade receivables is raised when there is objective evidence that the consolidated entity will not be able to collect all amounts due according to the original terms of the receivables.

**Nexsen Limited****Notes to the Financial Statements  
For the Year Ended 30 June 2025****2 Material Accounting Policy Information****(h) Intangible assets****Research and development**

Expenditure during the research phase of a project is recognised as an expense when incurred. Development costs are capitalised only when technical feasibility studies identify that the project will deliver future economic benefits and these benefits can be measured reliably.

The expenditure capitalised includes the cost of materials, direct labour and overhead costs that are directly attributable to preparing the asset for its intended use. Other development expenditure is recognised in profit or loss as incurred.

Capitalised development costs are measured at cost less accumulated amortisation and accumulated impairment losses.

**(i) Impairment of non-financial assets**

At the end of each reporting period the Group determines whether there is evidence of an impairment indicator for non-financial assets.

Where an indicator exists and regardless for goodwill, indefinite life intangible assets and intangible assets not yet available for use, the recoverable amount of the asset is estimated.

**(j) Trade and other payables**

These amounts represent liabilities for goods and services provided to the consolidated entity prior to the end of the financial year and which are unpaid. Due to their short-term nature, they are measured at amortised cost and are not discounted. The amounts are unsecured and are usually paid within 30 days of recognition.

**(k) Convertible Notes**

Convertible notes are initially recognized as financial liabilities at their fair value, net of transaction costs. Interest expense is recognized using the effective interest rate method. The liability component is measured at amortized cost. Upon conversion, the carrying amount of the liability is reclassified to equity. Any difference between the carrying amount and the fair value of the equity issued is recognized in equity.

**(l) Adoption of new and revised accounting standards**

The Group has adopted all standards which became effective for the first time at 30 June 2025, the adoption of these standards has not caused any material adjustments to the reported financial position, performance or cash flow of the Group or refer to Note for details of the changes due to standards adopted.

## Nexsen Limited

# Notes to the Financial Statements

For the Year Ended 30 June 2025

## 2 Material Accounting Policy Information

### (m) New accounting standards and interpretations issued but not yet effective

#### New accounting standards for application in future periods

The AASB has issued new and amended Accounting Standards and Interpretations that have mandatory application dates for future reporting periods. The Group has decided not to early adopt these Standards. The following table summarises those future requirements, and their impact on the Group where the standard is relevant:

AASB No.	Title	Application date*	Issue date
AASB 2023-5	Amendments to Australian Accounting Standards – Lack of Exchangeability	1 Jan 2025	October 2023
AASB 2024-2	Amendments to Australian Accounting Standards - Classification and Measurement of Financial Instruments	1 Jan 2026	July 2024
AASB 2024-3	Amendments to Australian Accounting Standards - Annual Improvements Volume 11	1 Jan 2026	2024
AASB 2025-1	Amendments to Australian Accounting Standards - Contracts Referencing Nature-dependent Electricity	1 Jan 2026	February 2025
AASB 18	Presentation and Disclosures of Financial Statements	1 Jan 2027	2024–2025
AASB 2024-4	Amendments to AASB 10 Consolidated Financial Statements and AASB 128 Investments in Associates and Joint Ventures - Sale or contribution of assets between an investor and its associates or joint venture	1 Jan 2028	November 2024

\*Annual reporting periods beginning after

## 3 Critical Accounting Estimates and Judgments

The directors make estimates and judgements during the preparation of these consolidated financial statements regarding assumptions about current and future events affecting transactions and balances.

These estimates and judgements are based on the best information available at the time of preparing the financial statements, however as additional information is known then the actual results may differ from the estimates.

The significant estimates and judgements made have been described below.

### Key estimates - Impairment of Intangible Assets

The Group assesses impairment of intangible assets at the end of each reporting period by evaluating the conditions and events specific to the Group that may be indicative of impairment triggers. Recoverable amounts of relevant assets are reassessed using value-in-use calculations which incorporate various key assumptions.

## Nexsen Limited

## Notes to the Financial Statements

### For the Year Ended 30 June 2025

#### 4 Other Revenue and Income

##### Revenue from continuing operations

	2025	2024
	\$	\$
Grants received	931,605	625,925

##### Other Income

	2025	2024
	\$	\$
Other income	-	5,938

#### 5 Finance Expenses

	2025	2024
	\$	\$
Borrowing costs	2,340,060	65,820
Interest expenses	2,347	1,026
<b>Total finance expenses</b>	<b>2,342,407</b>	<b>66,846</b>

#### 6 Cash and Cash Equivalents

	2025	2024
	\$	\$
Cash at bank	423,104	591,522
	<b>423,104</b>	<b>591,522</b>

#### 7 Trade and Other Receivables

	2025	2024
	\$	\$
CURRENT		
GST receivable	230,284	-
Other receivables	-	49,815
<b>Total current trade and other receivables</b>	<b>230,284</b>	<b>49,815</b>

##### Trade and other receivables classified as financial assets at amortised cost

	2025	2024
	\$	\$
Trade and Other Receivables	230,284	49,815
Less: GST receivable	(230,284)	-
	<b>-</b>	<b>49,815</b>

## Nexsen Limited

## Notes to the Financial Statements

### For the Year Ended 30 June 2025

#### 8 Intangible Assets

	2025	2024
	\$	\$
Development costs - sensor point of care rapid test Cost	1,714,629	433,510
	<u>1,714,629</u>	<u>433,510</u>
Other Intellectual Property Cost	250,000	250,000
	<u>250,000</u>	<u>250,000</u>
<b>Total Intangible assets</b>	<u><u>1,964,629</u></u>	<u><u>683,510</u></u>

#### Movements in carrying amounts of intangible assets

	Research and development costs	Other Intellectual Property	Total
	\$	\$	\$
<b>Year ended 30 June 2025</b>			
Balance at the beginning of the year	433,510	250,000	683,510
Additions	1,281,119	-	1,281,119
	<u>1,714,629</u>	<u>250,000</u>	<u>1,964,629</u>
<b>Closing value at 30 June 2025</b>	<u><u>1,714,629</u></u>	<u><u>250,000</u></u>	<u><u>1,964,629</u></u>

The \$1.28M increase in Research and development costs is associated with the issue of 6.0 million shares and the payment of \$250,000 in cash to RMIT, in exchange for the transfer of intellectual property rights titled "Diagnostic Aptamer" in respect of Aptamers for Group B Streptococci and related methods.

**Nexsen Limited**

**Notes to the Financial Statements**  
**For the Year Ended 30 June 2025**

**9 Trade and Other Payables**

	<b>2025</b>	<b>2024</b>
	<b>\$</b>	<b>\$</b>
CURRENT		
Trade payables	<b>106,028</b>	71,455
GST payable	-	73,888
Employee benefits payable	<b>147,901</b>	-
	<b>253,929</b>	145,343

Trade and other payables are unsecured, non-interest bearing and are normally settled within 30 days. The carrying value of trade and other payables is considered a reasonable approximation of fair value due to the short-term nature of the balances.

**Trade and other payables classified as financial liabilities at amortised cost**

	<b>2025</b>	<b>2024</b>
	<b>\$</b>	<b>\$</b>
Trade and Other Payables	<b>106,028</b>	145,343
Less: GST payable	-	(73,888)
	<b>106,028</b>	71,455

**10 Other Financial Liabilities**

	<b>2025</b>	<b>2024</b>
	<b>\$</b>	<b>\$</b>
CURRENT		
Convertible notes	<b>3,120,000</b>	-
<b>Total</b>	<b>3,120,000</b>	-

An issue of convertible notes was completed in February 2025. The convertible notes are expected to be converted upon the Company achieving an ASX listing at a 50% discount to the IPO share price.

## Nexsen Limited

## Notes to the Financial Statements

For the Year Ended 30 June 2025

## 11 Issued Capital

	2025	2024
	\$	\$
128,996,200 (2024: 61,498,100 ) Ordinary shares	2,521,561	1,321,561
<b>Total</b>	<b>2,521,561</b>	<b>1,321,561</b>

## (a) Ordinary shares

	2025	2024
	No.	No.
At the beginning of the reporting period	61,498,100	53,500,000
2 for 1 share split dated 12 December 2024	61,498,100	-
Shares issued during the year	6,000,000	7,998,100
At the end of the reporting period	<b>128,996,200</b>	61,498,100

The holders of ordinary shares are entitled to participate in dividends and the proceeds on winding up of the Company. On a show of hands at meetings of the Company, each holder of ordinary shares has one vote in person or by proxy, and upon a poll each share is entitled to one vote.

The Company does not have authorised capital or par value in respect of its shares.

## (b) Capital management

The key objectives of the Company when managing capital is to safeguard its ability to continue as a going concern and maintain optimal benefits to stakeholders. The Company defines capital as its equity and net debt.

There has been no change to capital risk management policies during the year.

The Company manages its capital structure and makes funding decisions based on the prevailing economic environment and has a number of tools available to manage capital risk. These include the issue of new shares.

The Board monitors a range of financial metrics including return on capital employed and gearing ratios.

## 12 Contracted Commitments

On February 22, 2024, Nexsen executed a CRC-P Grant Agreement with RMIT and D&I Pty Ltd. A variation to this agreement was executed on July 3, 2024, which removed a party and increased Nexsen's contribution.

Nexsen has committed to paying approximately \$1.8 million over a period of 2.5 years under its research agreements. In addition to these cash commitments, the Company also has in-kind and staff commitments as part of its research agreements.

## Nexsen Limited

## Notes to the Financial Statements

### For the Year Ended 30 June 2025

#### 13 Financial Risk Management

		2025	2024
		\$	\$
<b>Financial assets</b>			
Held at amortised cost			
Cash and cash equivalents	6	423,104	591,522
Trade and other receivables	7	-	49,815
<b>Total financial assets</b>		<b>423,104</b>	<b>641,337</b>
<b>Financial liabilities</b>			
Trade and other payables	9	106,028	71,455
Other financial liabilities	10	3,120,000	-
<b>Total financial liabilities</b>		<b>3,226,028</b>	<b>71,455</b>

#### Objectives, policies and processes

The Board of Directors have overall responsibility for the establishment of the Group's financial risk management framework. This includes the development of policies covering specific areas such as foreign exchange risk, interest rate risk, liquidity risk, credit risk and the use of derivatives.

Risk management policies and systems are reviewed regularly to reflect changes in market conditions and the Group's activities.

The day-to-day risk management is carried out by the Group's finance function under policies and objectives which have been approved by the Board of Directors. The Chief Financial Officer has been delegated the authority for designing and implementing processes which follow the objectives and policies. This includes monitoring the levels of exposure to interest rate and foreign exchange rate risk and assessment of market forecasts for interest rate and foreign exchange movements.

The Board of Directors receives monthly reports which provide details of the effectiveness of the processes and policies in place.

Mitigation strategies for specific risks faced are described below:

#### Liquidity risk

The Group manages its liquidity needs by carefully monitoring scheduled debt servicing payments for long-term financial liabilities as well as cash-outflows due in day-to-day business.

Liquidity needs are monitored in various time bands, on a day-to-day and week-to-week basis, as well a rolling 30-day projection. Long-term liquidity needs for a 180-day and a 360-day period are identified monthly.

At the reporting date, these reports indicate that the Group expected to have sufficient liquid resources to meet its obligations under all reasonably expected circumstances.

The earliest contractual settlement for payables and borrowings is less than 12 months.

## Nexsen Limited

# Notes to the Financial Statements

## For the Year Ended 30 June 2025

### 13 Financial Risk Management

#### Credit risk

Credit risk refers to the risk that a counterparty will default on its contractual obligations resulting in a financial loss to the Group.

Credit risk arises from cash and cash equivalents, deposits with banks and financial institutions including outstanding receivables and committed transactions.

The credit risk for liquid funds and other short-term financial assets is considered negligible, since the counterparties are reputable banks with high quality external credit ratings.

#### Market risk

Market risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices.

### 14 Key Management Personnel Remuneration

The remuneration paid to key management personnel of the Company and the Group is \$ 543,828 (2024: \$ 341,056).

### 15 Auditors' Remuneration

	2025	2024
	\$	\$
Audit of the financial statements	20,000	10,000
Compilation of the financial statements	-	5,000
<b>Total</b>	<b>20,000</b>	<b>15,000</b>

### 16 Interests in Subsidiaries

#### (a) Composition of the Group

Subsidiaries	Principal place of business / Country of Incorporation	Percentage owned (%)*	Percentage owned (%)*
		2025	2024
Nexgen Nanosensors Pty Ltd	Australia	100	100

\*The percentage of ownership interest held is equivalent to the percentage voting rights for all subsidiaries.

### 17 Contingent Liabilities

In the opinion of the Directors, the Company did not have any contingent liabilities at 30 June 2025 (30 June 2024: None).

## Nexsen Limited

## Notes to the Financial Statements

For the Year Ended 30 June 2025

## 18 Related Parties

## (a) The Group's main related parties are as follows:

Key management personnel - refer to Note 14.

Other related parties include close family members of key management personnel and entities that are controlled or significantly influenced by those key management personnel or their close family members.

## (b) Transactions with related parties

Transactions between related parties are on normal commercial terms and conditions no more favourable than those available to other parties unless otherwise stated.

	2025	2024
	\$	\$
<b>KMP related parties</b>		
Amounts paid to a company controlled by Mr Gavin Ball for services related to investor relations and promotional activities	158,730	59,924
Amounts paid to a company controlled by Mr Mark Muzzin	103,958	-

## (c) Loans to/from related parties

	2025	2024
	\$	\$
Amounts payable at year end to Mr M Muzzin, included in trade payables	-	9,065

## 19 Cash Flow Information

## Reconciliation of result for the year to cashflows from operating activities

Reconciliation of net income to net cash provided by operating activities:

	2025	2024
	\$	\$
Profit for the year	(5,021,842)	827
Cash flows excluded from profit attributable to operating activities		
Non-cash flows in profit:		
- amortisation of convertible notes	2,340,000	-
Changes in assets and liabilities:		
- increase in trade and other receivables	(180,469)	(41,294)
- increase in other assets	(453,574)	(142,486)
- increase in trade and other payables	108,586	139,405
Cashflows from operations	<u>(3,207,299)</u>	<u>(43,548)</u>

## Nexsen Limited

## Notes to the Financial Statements

For the Year Ended 30 June 2025

## 20 Events Occurring After the Reporting Date

No matters or circumstances have arisen since the end of the financial year which significantly affected or could significantly affect the operations of the Group, the results of those operations, or the state of affairs of the Group in future financial years.

## 21 Parent Entity

	2025	2024
	\$	\$
<b>Consolidated Statement of Financial Position</b>		
Assets		
Current assets	1,293,056	827,431
Non-current assets	1,964,629	683,510
Total Assets	<u>3,257,685</u>	<u>1,510,941</u>
Liabilities		
Current liabilities	3,373,929	145,343
Total Liabilities	<u>3,373,929</u>	<u>145,343</u>
Equity		
Issued capital	2,521,561	1,321,561
Retained earnings	(5,230,115)	(208,273)
General reserve	2,592,310	252,310
Total Equity	<u>(116,244)</u>	<u>1,365,598</u>
<b>Consolidated Statement of Profit or Loss and Other Comprehensive Income</b>		
Total profit or loss for the year	<u>(5,021,842)</u>	827
<b>Total comprehensive income</b>	<u>(5,021,842)</u>	<u>827</u>

## 22 Statutory Information

The registered office of the company is:

SUITE 1005  
4 BRIDGE STREET  
SYDNEY NSW 2000

The principal place of business is:

UNIT 10 L  
440 COLLINS STREET  
MELBOURNE VIC 3000

## Consolidated Entity Disclosure Statement For the Year Ended 30 June 2024

Entity name	Entity type	Country of incorporation	Ownership interest %	Tax residency & foreign jurisdiction
Nexgen Nanosensors Pty Ltd	Australian Proprietary Company, Limited By Shares	Australia	100%	Australia

personal use only

**Nexsen Limited**

**Directors' Declaration**


In the directors' opinion:

1. the consolidated financial statements and notes for the year ended 30 June 2025 are in accordance with the *Corporations Act 2001* and:
  - a. complying with Accounting Standards which, as stated in basis of preparation Note 1 to the consolidated financial statements, constitutes compliance with International Financial Reporting Standards (IFRS); and
  - b. giving a true and fair view of the financial position and performance of the consolidated group.
2. The information disclosed in the attached consolidated entity disclosure statement is true and correct.
3. there are reasonable grounds to believe that the Company will be able to pay its debts as and when they become due and payable with the continuing support of creditors.

This declaration is made in accordance with a resolution of the Board of Directors.

Signed by:  


Director .....  
6217F44D97CF49C.....  
Mark Anthony Muzzin

Signed by:  


Director .....  
497B543B661B438.....  
Reece O'Connell

Dated 21 August 2025

For personal use only

**INDEPENDENT AUDITOR'S REPORT  
TO THE MEMBERS OF NEXSEN LIMITED****Report on the Audit of the Financial Report****Opinion**

We have audited the consolidated financial report of Nexsen Limited (the Company), which comprises the statement of financial position as at 30 June 2025, the statement of profit or loss and other comprehensive income, the statement of changes in equity and the statement of cash flows for the year then ended, and notes to the financial statements, including a summary of material accounting policies, and the directors' declaration.

In our opinion, the accompanying financial report of the Company is in accordance with the *Corporations Act 2001*, including:

- i. giving a true and fair view of the consolidated financial position of the Company as at 30 June 2025 and of its consolidated financial performance for the year then ended; and
- ii. complying with Australian Accounting Standards and the Corporations Regulations 2001.

**Basis for Opinion**

We conducted our audit in accordance with Australian Auditing Standards. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Report section of our report.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

**Material Uncertainty Related to Going Concern**

We draw attention to Note 1 of the financial report, which indicates that the Company's ability to continue as a going concern for at least the next 12 months is dependent upon its ability to obtain funding or financing necessary, from either shareholders or new investors. These conditions indicate the existence of a material uncertainty that may cast doubt about the Company's ability to continue as a going concern and therefore, the Company may be unable to realise its assets and extinguish its liabilities in the normal course of business and at the amounts stated in the financial report. Our audit opinion is not modified in this regard.

**Independence**

We are independent of the Company in accordance with the auditor independence requirements of the *Corporations Act 2001* and the ethical requirements of the Accounting Professional and Ethical Standards Board's APES 110 *Code of Ethics for Professional Accountants (including Independence Standards)* (the "Code") that are relevant to our audit of the financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

## INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF NEXSEN LIMITED (CONTINUED)

### Other Information

The directors are responsible for the other information. The other information comprises the information included in the Company's annual report for the year ended 30 June 2025 but does not include the financial report and our auditor's report thereon.

Our opinion on the financial report does not cover the other information and accordingly we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial report, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial report, or our knowledge obtained in the audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

### Responsibilities of the Directors for the Financial Report

The directors of the Company are responsible for the preparation of the financial report that gives a true and fair view in accordance with Australian Accounting Standards and the *Corporations Act 2001* and for such internal control as the directors determine is necessary to enable the preparation of the financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

In preparing the financial report, the directors are responsible for assessing the ability of the Company to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

### Auditor's Responsibilities for the Audit of the Financial Report

Our objectives are to obtain reasonable assurance about whether the financial report as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with the Australian Auditing Standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this financial report.

A further description of our responsibilities for the audit of the financial report is located at the Auditing and Assurance Standard Board website at [http://www.auasb.gov.au/auditors\\_responsibilities/ar4.pdf](http://www.auasb.gov.au/auditors_responsibilities/ar4.pdf). This description forms part of our audit report.



NEIL PACE  
PARTNER



MOORE AUSTRALIA AUDIT (WA)  
CHARTERED ACCOUNTANTS

Signed at Perth this 21<sup>st</sup> day of August 2025.